About ▼ Careers Internship MedBlog Contact us

LOGIN REGISTER

Medindia » News » Drug News » Cystic Fibrosis Drug by Pharmaxis Requires Another Trial to Get FDA Approval

Cystic Fibrosis Drug by Pharmaxis Requires Another Trial to Get FDA Approval

by Raja Nandhini on Mar 21 2013 7:32 AM

Cystic Fibrosis Drug by Pharmaxis Requires Another Trial to Get FDA Approval

FDA has denied approval to market the drug, Bronchitol, manufactured by the Australian biotechnology company, Pharmaxis, in US market.

The dry powder formulation of mannitol (Bronchitol) is designed to treat cystic fibrosis. It is approved in Australia for patients above six years of age and for adults above 18 years old in European Union.

Clinical Trials and Its different Phases

Clinical Trials and Its different Phases
Clinical trials serve as a vital component for improving the treatment of medical conditions as they lead to higher standards of patient care.

The review committee has rejected the approval stating that an additional trial is required to prove the efficacy of the drug. FDA has noted that the first two clinical trial data submitted by the company do not meet benefit- risk balance. The first trial had too many early dropouts while the second study failed to produce statistically significant results.

Gary Phillips, CEO of Pharmaxis has announced that the company is ready to work with FDA and take the required measured to gain approval.

Source-Medindia

Extensive Study Probes New Concerns on Antibiotic Use for Cystic Fibrosis

Extensive Study Probes New Concerns on Antibiotic Use for Cystic Fibrosis
When concerning treating cystic fibrosis, the existing standard of aggressive antibiotic treatments may not at all times be the best answer, discovers a decade-long study led by researchers.

People With Cystic Fibrosis Who Live in Deprived Areas Have Worse Health

People With Cystic Fibrosis Who Live in Deprived Areas Have Worse Health
People with Cystic Fibrosis (CF) who live in deprived areas have worse growth and lung function than people living in more advantaged areas, finds a study by the University of Liverpool.

Recommended Readings

Retroperitoneal Fibrosis / Ormond´s Disease

Retroperitoneal Fibrosis / Ormond´s Disease

Retroperitoneal fibrosis or Ormond's disease a rare disorder occurs when extra fibrous tissue forms in the area behind the stomach and intestines.

Genetic Testing of Diseases

Genetic Testing of Diseases

Genetic testing helps to confirm a genetic condition in an individual and involves q complex laboratory techniques

Cystic Fibrosis

Cystic Fibrosis

Cystic fibrosis is a genetic disease involving the mucus and sweat glands and the medical world has still to find its cure

Fibroscan for Fatty Liver Cirrhosis and Fibrosis

Fibroscan for Fatty Liver Cirrhosis and Fibrosis

Recently, Fibroscan has incorporated the noninvasive Controlled Attenuation Parameter technique to estimate the degree of fatty infiltration in the liver.

Drug Toxicity

Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a drug, reaction to a drug or drug abuse.

Latest Drug News

US FDA Approval of N-803: Ray of Hope For Bladder Cancer Patients

US FDA Approval of N-803: Ray of Hope For Bladder Cancer Patients

The US FDA approves a immunotherapy drug, N-803, for BCG-unresponsive non-muscle invasive bladder cancer, suggested to be used in conjunction with BCG.

Resmetirom For MASH: Approved by US FDA, Increase in Partnerships

Resmetirom For MASH: Approved by US FDA, Increase in Partnerships

The increasing trend in strategic partnerships between innovator companies, and the US FDA approval for Rezdiffra has led to a boost in the development of medications for MASH.

Semaglutide: A Dominant Player for Patients With Heart Failure

Semaglutide: A Dominant Player for Patients With Heart Failure

Data provesSemaglutideefficacy in treatment of Type 2 diabetes, obesity, heart failure, and chronic kidney failure, it emerges as important therapy in metabolic syndrome.

Physician's Lack Agreement – Patients Prefer Branded or Generic Drugs?

Physician's Lack Agreement – Patients Prefer Branded or Generic Drugs?

Generics are not widely used, despite cost advantage, due to a lack of information to patients and reluctance from physicians to prescribe generics - A Need to educate masses

Drug Resistant Melanoma Caused Due to Break in Genes!

Drug Resistant Melanoma Caused Due to Break in Genes!

Studies have led to discovery that drug-resistant melanomas are caused by breaks in the genes, thereby leading to emphasis on alternate targeted therapies to combat cancer.

Advertisement